

# ForPatients

*by Roche*

Multiple Sclerosis (MS) Primary Progressive Multiple Sclerosis (PPMS)

## A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

**Trial Status**  
Completed

**Trial Runs In**  
29 Countries

**Trial Identifier**  
NCT01194570 2010-020338-25  
WA25046

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT01194570 2010-020338-25 WA25046**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years & <= 55 Years

**Healthy Volunteers**  
No

---